Ask HopeStage to review this study with me
Study ID: NCT04532749. We help you review the study, but cannot decide medical eligibility.
TerminatedNCT04532749
Seltorexant 20 mg for depression
This study was terminated in the United States, in Argentina, in Chile, .... It is testing Seltorexant 20 mg for depression.
DepressionDrugFrom 18 Years to 74 Years
Key information made simple
This summary needs review. Please check the official study record and contact the research team for details.
Your next step
The official record does not clearly describe the visit format, so the practical details are best checked directly in the source. Participation appears to involve study activities and follow-up chosen by the research team. The main fit and exclusions are best confirmed in the eligibility section of the official record. The phase details are not clearly stated here.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: September 15, 2020
- Recruitment status
- Terminated
- Estimated enrollment
- Not clearly listed
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States, Argentina, Chile, ...
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT04532749
- Official title
- A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT04532749. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Who might this study be for?
This study may concern people with depression; age range: From 18 Years to 74 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Janssen Research & Development, LLC, which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is not currently recruiting. Check the official registry for the reason and latest status.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
TerminatedNCT02389712
16-week Comparative Effectiveness study of Lamotrigine vs. Fluoxetine for Depression in bipolarity
This study has public registry information. It focuses on bipolarity and currently lists study information in the United States.
TerminatedNCT05169710
Investigational Drug for depression
This study was terminated in the United States, in Canada, in Bulgaria, .... It is testing investigational Drug for depression.
TerminatedNCT05227209
Safety study of investigational Drug in depression
This study was terminated in the United States, in Bulgaria, and in Japan. It is testing investigational Drug for depression.